Abbisko Therapeutics
Manufacturing · China · 201-500 Employees
View Company Info for Free
Overview
Headquarters
898 Halei Rd Building 3, Pudong New Area...Phone Number
+86 914180Website
www.abbisko.comRevenue
$16.9 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Abbisko Therapeutics
Abbisko Therapeutics is a biopharmaceutical company founded in 2016, focused on discovering and developing novel therapies for cancer and other unmet medical needs. The company has established a strong in-house R&D engine and a diverse pipeline of over 10 small molecule programs, primarily targeting oncology. Led by a seasoned management team with extensive experience in drug development, Abbisko aims to address critical healthcare challenges for patients in China and globally. The company actively seeks partnerships and collaborations with industry and academic leaders to enhance its research and development efforts.Explore more
Abbisko Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Abbisko Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Abbisko Therapeutics launches new products
Check if Abbisko Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Abbisko Therapeutics has new funding data
Click to see if Abbisko Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check out if Abbisko Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Abbisko Therapeutics
Abbisko Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Abbisko Therapeutics recently announced quarterly report
Recommended Actions
Find VP level buyers at Abbisko Therapeutics
Find 3 more new buyers
Company Profile Activity
Activity Insights
Abbisko Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Abbisko Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Abbisko Therapeutics.
Abbisko Therapeutics financials insights
Gather financial insights about Abbisko Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Other Financing Round
$123M
Abbisko Therapeutics Tech Stack
A closer look at the technologies used by Abbisko Therapeutics
See more technologies
Most Recent Scoops
Person-Based
Person-Based
New Hire
Executive Move
Abbisko Therapeutics has announced that Richard Yeh has joined the company as Chief Operating Officer. Previously, Yeh was Chief Financial Officer & Head of Strategic Operations for Abbisko Therapeutics.
Left Company
Executive Move
Richard Yeh, Chief Financial Officer & Head of Strategic Operations, has recently left the company to join I-Mab Biopharma as Chief Operating Officer.
Funding
Abbisko Therapeutics News & Media
Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
SHANGHAI, July 2, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic collaboration agreement with AstraZeneca (LSE/STO/NYSE: AZN) to jointly advance the clinical development of a novel IO-TKI combination therapy for non-small cell lung cancer (NSCLC). As a multicenter, open-label Phase I/II clinical study, the combination will evaluate the safety and efficacy of Abbisko's first-in-classAbbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
SHANGHAI, July 1, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic collaboration agreement with AstraZeneca (LSE/STO/NYSE: AZN) to jointly advance the clinical development of a...Abbisko Therapeutics Deepens R&D Collaboration with Lilly
SHANGHAI, June 23, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic research collaboration and license agreement with Eli Lilly and Company ("Lilly"), a leading global...Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor
SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- 13 January 2026 (Beijing Time), Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announced today that the New Drug Application (NDA) for its novel, orally administered, highly selective, and potent...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Abbisko Therapeutics
Sign Up For FreeTo access detailed company insights
Abbisko Therapeutics is a biopharmaceutical company founded in 2016, focused on discovering and developing novel therapies for cancer and other unmet medical needs. The company has established a strong in-house R&D engine and a diverse pipeline of over 10 small molecule programs, primarily targeting oncology. Led by a seasoned management team with... Read More
